Pheburane Pellet
NDC Package 71770-210-10
Package Information
Pheburane (sodium phenylbutyrate) pellets is pHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS).Limitations of UseEpisodes of acute hyperammonemia may occur in patients while on PHEBURANE. This formulation utilizes a pellet delivery system. Marketed by Medunik Usa, this product is identified by NDC 71770-210 and is authorized under FDA application NDA216513.
Identification & Billing
- RxCUI: 2610128 - sodium phenylbutyrate 483 MG/GM Oral Pellet
- RxCUI: 2610128 - sodium phenylbutyrate 0.483 MG/MG Oral Pellet
- RxCUI: 2610134 - Pheburane 483 MG/GM Oral Pellet
- RxCUI: 2610134 - sodium phenylbutyrate 0.483 MG/MG Oral Pellet [Pheburane]
- RxCUI: 2610134 - Pheburane 0.483 MG/MG Oral Pellet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71770 - Medunik Usa
- 71770-210 - Pheburane
- 71770-210-10 - 174 g in 1 BOTTLE
- 71770-210 - Pheburane
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71770-210-10 identifies a specific commercial package of 174 g in 1 bottle of Pheburane, a human prescription drug labeled by Medunik Usa. This pellet is formulated for oral use and contains sodium phenylbutyrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Medunik Usa on September 14, 2022. The current certification is valid through December 31, 2027.
How is this Medunik Usa product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71770021010. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.